A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of EN3835 In The Treatment Of Edematous Fibrosclerotic Panniculopathy (Cellulite)
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 08 Aug 2018
At a glance
- Drugs Collagenase clostridium histolyticum (Primary)
- Indications Cellulite
- Focus Registrational; Therapeutic Use
- Acronyms RELEASE-1
- Sponsors Endo Pharmaceuticals
- 08 Aug 2018 According to an Endo Inernational media release, topline results anticipated in fourth-quarter 2018.
- 09 Jul 2018 Status changed from recruiting to active, no longer recruiting.
- 14 Mar 2018 According to a BioSpecifics Technologies Corporation media release, top-line results are expected in the first quarter of 2019.